Ablexis Announces License Agreement with Adimab

Your unfiltered news center. ®

The world you see depends upon the news you get. ®

HOME

ARTS

RSS

Today's Date: April 18, 2024

Yom HaAliyah: The International Fellowship of Christians and Jews Celebrates Helping Thousands of Jews Make Aliyah in 2023 • CF Industries Holdings, Inc. Declares Quarterly Dividend and Confirms Dates for First Quarter 2024 Results and Conference Call • Targeting A Solution Panel Aims to Find Solutions for the Veteran Suicide Crisis with National Thought Leaders Tulsi Gabbard, Ti • Sundial Media Group Extends Its Reach, Further Diversifying the Media Landscape • The UAE’s Largest Higher Education Institution, Higher Colleges of Technology, Selects YuJa Video Platform to Serve More t • Canada brings the world together in pursuit of an ambitious global deal to end plastic pollution • SuperWomen Of FMS Leadership Award Nominations Now Open • Semrush Holdings, Inc. Announces Investor Conference Call to Review First Quarter 2024 Financial Results • First Annual U.S.-Ukraine Veterans' Charity Golf Tournament Announced with General Retired David Petraeus as Guest of Honor • Dr. Cathleen Brown Named Medical Director of Winona, Pioneering Menopause Telehealth Company • Nationally Syndicated “The Bert Show” Hosts Candid Interview with Usher, Who Credits Top Morning-Drive Radio Intervi • Angels Helpers NYC Announces 2024 Charity Gala “Big City, Big Hearts: New Yorkers Helping New Yorkers” • Wheels in Motion: Nationwide Ride of a Life Time Cycling Event Set for April 27 to Support Children's Health • Franklin Covey Announces New Common Share Purchase Plan • Genome-wide association analyses identify 95 risk loci and provide insights into the neurobiology of post-traumatic stress disor • WK Kellogg Co and Meijer Donate $50,000 to Battle Creek Public Schools Mission Tiger • RepTrak Announces 2024 Global RepTrak® 100 Report • Bright Horizons Family Solutions Announces Date of First Quarter 2024 Earnings Release and Conference Call • Dr. Laurie Leshin, Director of JPL, to Receive THE MUSES of the California Science Center Foundation 2024 Woman of the Year Awar • Innovafeed Expands to U.S.; French Agtech Firm Opens Insect Innovation Center in Decatur, Ill.

Ablexis Announces License Agreement with Adimab

SAN DIEGO , February 09 /Businesswire/ - Ablexis, LLC, a biopharmaceutical company focused on licensing its AlivaMab Mouse technology for antibody drug discovery, today announced a license agreement with Adimab, LLC (“Adimab”). The non-exclusive license grants Adimab rights to implement select strains of AlivaMab Mouse into its proprietary yeast-based technology for antibody drug discovery for its clients. Financial terms of the license were not disclosed.

“Ablexis is pleased that Adimab has selected AlivaMab Mouse for integration into its suite of technology offerings to clients,” said Larry Green, Ph.D., Chief Executive Officer of Ablexis. “Adimab and Ablexis share an understanding that quality is the biggest driver enabling highly competitive programs to reach the clinic and market. AlivaMab Mouse met Adimab’s exacting standards, which included mounting immune responses against different targets that have historically been considered challenging, successful implementation into Adimab’s proprietary yeast-based technology platform, diversity of the antigen-specific IgG repertoire, and developability of AlivaMab antibodies,” Dr. Green continued.

“Adimab has invested heavily in its approach to membrane targets, which has led to novel immunization strategies and isolation techniques leveraging our proprietary and highly validated yeast-based platform,” said Eric Krauland, Ph.D., President and Chief Scientific Officer of Adimab. “After analyzing the results of our rigorous multi-year evaluation, we are confident that the AlivaMab Mouse technology and its human antibody repertoire will fit seamlessly into our differentiated workflows to substantially enhance our offerings in this space.”

About Ablexis, LLC

Ablexis, LLC created and offers AlivaMab Mouse, a growing suite of unique, patented next generation transgenic mice, as a foundational platform for successful human antibody drug discovery and development. Dozens of companies, including 12 of the world’s top 25 global pharmaceutical companies, public and private biotechnology companies, and other entities have licensed AlivaMab Mouse for their antibody drug discovery. Ablexis’ sister company, AlivaMab Discovery Services, led by scientists with over a cumulative century of experience in antibody drug discovery, provides an integrated antibody therapeutic discovery and engineering platform using the AlivaMab Mouse technologies. For more information, please visit www.ablexis.com, www.alivamab.com, or contact us at info@ablexis.com.